Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 30, 2006 - Issue 1
93
Views
18
CrossRef citations to date
0
Altmetric
PROCEEDINGS 15TH ICOCTAIWAN, APRIL 2005; PART 1. GUEST EDITORS: PROFESSORS CHING-TIEN PENG AND SUTHAT FUCHAROEN

Deferiprone or Deferoxamine vs. Combination Therapyin Patients with β-Thalassemia Major: A Case Studyin Taiwan

, , , , , , & show all
Pages 125-130 | Published online: 07 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Adriana Ceci, Rosa Conte, Antonella Didio, Donato Bonifazi, Mariagrazia Felisi, Viviana Giannuzzi & Fedele Bonifazi. (2019) An overview of the efficacy and safety of deferiprone in paediatric patients with congenital haemoglobinopathies and chronic iron overload. Expert Opinion on Orphan Drugs 7:4, pages 181-197.
Read now
Vip Viprakasit, Sarayuth Rodmai & Somdet Srichairatanakool. (2014) Deferiprone for transfusional iron overload and its roles in developing countries. Expert Opinion on Orphan Drugs 2:2, pages 189-200.
Read now
Ching-Tien Peng, Jeng-Sheng Chang, Lin-Yen Wang, Shyh-Shin Chiou, Chih-Cheng Hsiao, Shih-Chung Wang, Giun-Yi Hung & Kang-Hsi Wu. (2009) Update on Thalassemia Treatment in Taiwan, Including Bone Marrow Transplantation, Chelation Therapy, and Cardiomyopathy Treatment Effects. Hemoglobin 33:5, pages 304-311.
Read now

Articles from other publishers (13)

Yesim Aydinok. (2023) Combination chelation therapy. Annals of the New York Academy of Sciences 1529:1, pages 33-41.
Crossref
Nancy F. Olivieri, Amir Sabouhanian & Brenda L. Gallie. (2019) Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. PLOS ONE 14:2, pages e0211942.
Crossref
Han-Ping Wu, Cheng-Li Lin, Yin-Chen Chang, Kang-Hsi Wu, Rouh-Lih Lei, Ching-Tien Peng, Tefu Weng, Yu-Man Tai & Yu-Hua Chao. (2017) Survival and complication rates in patients with thalassemia major in Taiwan. Pediatric Blood & Cancer 64:1, pages 135-138.
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs 840 845 .
Wan-Ling Ho, Kuo-Piao Chung, Szu-Sheng Yang, Meng-Yao Lu, Shiann-Tarng Jou, Hsiu-Hao Chang, Yung-Li Yang, Dong-Tsamn Lin & Kai-Hsin Lin. (2013) A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. Journal of the Formosan Medical Association 112:4, pages 221-229.
Crossref
Vip Viprakasit, Hishamshah Ibrahim, Shau-Yin Ha, Phoebe Joy Ho, Chi-Kong Li, Lee-Lee Chan, Chang-Fang Chiu, Pranee Sutcharitchan, Dany Habr, Gabor Domokos, Bernard Roubert, Hong-Ling Xue, Donald K. Bowden & Kai-Hsin Lin. (2011) Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International Journal of Hematology 93:3, pages 319-328.
Crossref
Antonio Piga, Simona Roggero, Ilaria Salussolia, Davide Massano, Melania Serra & Filomena Longo. (2010) Deferiprone. Annals of the New York Academy of Sciences 1202:1, pages 75-78.
Crossref
John B. Porter. (2009) Optimizing iron chelation strategies in β-thalassaemia major. Blood Reviews 23, pages S3-S7.
Crossref
D.R. Richardson, D.S. Kalinowski, S. Lau, P.J. Jansson & D.B. Lovejoy. (2009) Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochimica et Biophysica Acta (BBA) - General Subjects 1790:7, pages 702-717.
Crossref
R.H.B. Meyboom. 2009. 399 407 .
Maria Domenica Cappellini. (2008) Long-term efficacy and safety of deferasirox. Blood Reviews 22, pages S35-S41.
Crossref
Ching-Tien Peng, Chang-Hai Tsai, Kang-Hsi Wu, Chih-Chao Hsu & Tao-Yu Sheng. (2007) Improvement of Cardiac Function in Thalassemia Patients Using Deferiprone. Tzu Chi Medical Journal 19:4, pages 192-199.
Crossref
Claudia R Morris, Sylvia T Singer & Mark C Walters. (2007) Clinical hemoglobinopathies: iron, lungs and new blood. Current Opinion in Internal Medicine 6:1, pages 60-71.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.